| Literature DB >> 26167240 |
Syed M Nurulain1, Shreesh Ojha1, Kornelia Tekes2, Mohammad Shafiullah1, Huba Kalasz3, Abdu Adem1.
Abstract
There are a great number of reports with assertions that oxidative stress is produced by organophosphorus compound (OPC) poisoning and is a cofactor of mortality and morbidity in OPC toxicity. In addition, antioxidants have been suggested as adjuncts to standard therapy. However, there is no substantial evidence for the benefit of the use of antioxidants in survival after acute intoxication of OPCs. The present study was conducted to assess the effectiveness of three non-enzymatic antioxidants (NEAOs), N-acetylcysteine (NAC), glutathione (GSH), and ascorbic acid (AA), in acute intoxication of adult male Wister rats with paraoxon. The efficacy of the antioxidants was estimated as both a pretreatment and a concurrent application along with the standard oxime, pralidoxime (2-PAM). Relative risk of death after 48 hours of application was estimated by Cox regression analysis. The results revealed no benefit of either tested NEAO to the improvement in survival of experimental rats. The application of these antioxidants was found to be deleterious when administered along with pralidoxime compared to the treatment with pralidoxime alone. It has been concluded that the tested non-enzymatic antioxidants are not useful in acute toxicity for improving survival rates. However, the individual toxic dynamics of diversified OPCs should not be overlooked and further studies with different OPCs are suggested.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26167240 PMCID: PMC4488549 DOI: 10.1155/2015/329306
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Cumulative relative risk of death overtime after coapplication of compounds. Cumulative relative risk (RR) of death overtime with simultaneous intraperitoneal (i.p.) injection of POX, PAM and NAC, and GSH and AA. The legends on the side are depicting the treatment groups. RR was estimated by Cox [23] analysis, adjusted for POX dose (high/low) for each of the time points examined (30 min and 1, 2, 3, 4, 24, and 48 h). Best protection was conferred by simultaneous PAM treatment only and poor protection was estimated for all non-enzymatic treatment alone. Efficacy of PAM was estimated to decrement when co-administered with antioxidants.
Cox analysis of the cumulative relative risk (RR) of death for co-administration of compounds, including 95% confidence interval (CI), of animals exposed to the paraoxon (POX) and adjusted for POX dose (high/low).
| Groups | RR ± SD | 95% CI | Significance |
|---|---|---|---|
| POX only | 1 | 0-0 | |
| POX + PAM + NAC | 0.66 ± 15 | 0.42–0.91 |
|
| POX + NAC | 1.04 ± 0.04 | 0.97–1.12 | NS |
| POX + PAM | 0.33 ± 0.03 | 0.23–0.43 |
|
| POX + PAM + GSH | 0.81 ± 0.13 | 0.61–1.02 |
|
| POX + GSH | 1.08 ± 0.03 | 1.03–1.14 | NS |
| POX + PAM + AA | 1.30 ± 0.12 | 1.10–1.49 |
|
| POX + AA | 0.85 ± 0.28 | 0.00–3.32 |
|
Mortality [%] after concurrent application of paraoxon, pralidoxime, and NEAO.
| Groups (G) | POX dose | 30 min | 1 hour | 2 hours | 3 hours | 4 hours | 24 hours | 48 hours |
|---|---|---|---|---|---|---|---|---|
| G1: POX only | 1/2 | 79/96 | 83/96 | 88/96 | 88/96 | 88/96 | 88/96 | 88/96 |
| G2: POX + PAM + NAC | 1/2 | 42/78 | 50/78 | 67/89 | 71/89 | 71/89 | 79/89 | 83/94 |
| G3: POX + NAC | 1/2 | 92/100 | 92/100 | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 |
| G4: POX + PAM | 1/2 | 8/75 | 8/79 | 13/79 | 17/79 | 25/79 | 25/83 | 29/83 |
| G5: POX + PAM + GSH | 1/2 | 75/75 | 83/75 | 92/83 | 92/92 | 92/96 | 92/96 | 96/96 |
| G6: POX + GSH | 1/2 | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 |
| G7: POX + PAM + AA | 1/2 | 67/83 | 67/88 | 79/88 | 83/92 | 88/92 | 92/92 | 92/92 |
| G8: POX + AA | 1/2 | 75/100 | 88/100 | 88/100 | 88/100 | 88/100 | 88/100 | 88/100 |
Figure 2Cumulative relative risk of death over time with pretreatment of compounds. Cumulative relative risk (RR) of death over time with pretreatment, intraperitoneal injections of antioxidants followed by i.p. administration of POX and PAM. The legends on the side are depicting the treatment groups. RR was estimated by Cox [23] analysis, adjusted for POX dose (high/low) for each of the time points examined (30 min, after 30 min, 1, 2, 3, 4, 24, and 48 h). Best protection was conferred by PAM pretreatment only followed by GSH pretreatment. Efficacy of PAM was estimated to decrement when administered with antioxidants. B/F denotes before.
Mortality [%] after pretreatments of NEAO and co-application of paraoxon and pralidoxime.
| Groups (G) | POX DOSE ( | 30 min | 1 hour | 2 hours | 3 hours | 4 hours | 24 hours | 48 hours |
|---|---|---|---|---|---|---|---|---|
| G1: POX only | 1/2 | 79/92 | 83/92 | 88/92 | 88/92 | 88/92 | 88/92 | 88/92 |
| G2: PAM before POX | 1/2 | 4/42 | 17/46 | 17/46 | 17/50 | 17/58 | 17/71 | 17/75 |
| G3: NAC before POX | 1/2 | 94/96 | 94/96 | 100/100 | 100/100 | 100/100 | 100/100 | 100/100 |
| G4: NAC before (POX + PAM) | 1/2 | 17/71 | 33/75 | 38/79 | 42/79 | 42/88 | 50/92 | 50/92 |
| G5: (POX + PAM) | 1/2 | 8/75 | 8/79 | 13/79 | 17/79 | 25/79 | 25/83 | 29/83 |
| G6: GSH before (POX + PAM) | 1/2 | 67/46 | 67/67 | 71/92 | 75/96 | 83/90 | 83/96 | 88/96 |
| G7: GSH before POX | 1/2 | 92/83 | 92/92 | 96/92 | 100/92 | 100/96 | 100/96 | 100/96 |
| G8: AA before (POX + PAM) | 1/2 | 58/83 | 63/83 | 75/88 | 79/92 | 96/92 | 96/92 | 96/96 |
| G9: AA before POX | 1/2 | 58/75 | 67/83 | 75/83 | 75/83 | 75/92 | 83/100 | 83/100 |
Cox analysis of the cumulative relative risk (RR) of death for pretreatment protocol, including 95% confidence interval (CI), of animals exposed to the paraoxon (POX) and adjusted for POX dose (high/low).
| Groups | RR ± SD | 95% CI | Significance |
|---|---|---|---|
| POX only | 1 | 0-0 | — |
| PAM before POX | 0.34 ± 0.19 | 0.04–0.64 |
|
| NAC before POX | 1.31 ± 0.24 | 0.93–1.70 | NS |
| NAC before (POX + PAM) | 0.63 ± 0.15 | 0.39–0.86 |
|
| POX + PAM | 0.47 ± 0.17 | 0.20–0.74 |
|
| GSH before (POX + PAM) | 0.93 ± 0.30 | 0.45–1.41 | NS |
| GSH before POX | 0.84 ± 0.39 | 0.94–1.48 |
|
| AA before | 1.29 ± 0.18 | 1.01–1.57 |
|
| AA before POX | 1.09 ± 0.30 | 0.00–4.08 | NS |